Abstract: The invention relates to a regimen for repeated treatment of a neuropathic condition, preferably peripheral neuropathic pain, comprising a first application of one or more high-concentration capsaicin and/or capsaicinoid topical dose units, preferably high-concentration capsaicin and/or capsaicinoid patches, followed by a second application of one or more high-concentration capsaicin and/or capsaicinoid topical dose units, preferably high-concentration capsaicin and/or capsaicinoid patches, wherein the time period between the first application and the second application is preferably shortened in order to increase the responder rate.
Abstract: The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
Type:
Application
Filed:
November 14, 2022
Publication date:
September 28, 2023
Applicant:
Grünenthal GmbH
Inventors:
Sven KUEHNERT, Rene KOENIGS, Achim KLESS, Anita WEGERT, Ingo KONETZKI, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER
Abstract: The invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
Type:
Application
Filed:
July 9, 2021
Publication date:
August 24, 2023
Applicant:
Gruenenthal GmbH
Inventors:
Jo ALEN, Florian JAKOB, Sebastian KRUEGER, Philipp BARBIE
Abstract: The invention relates to 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
Type:
Application
Filed:
January 30, 2023
Publication date:
June 15, 2023
Applicant:
Gruenenthal GmbH
Inventors:
Sven KUEHNERT, Rene Michael KOENIGS, Florian JAKOB, Achim KLESS, Anita WEGERT, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER
Abstract: The invention relates to 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
Type:
Application
Filed:
January 30, 2023
Publication date:
June 15, 2023
Applicant:
Gruenenthal GmbH
Inventors:
Sven KUEHNERT, Rene Michael KOENIGS, Achim KLESS, Anita WEGERT, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER
Abstract: The invention relates to 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
Type:
Application
Filed:
January 30, 2023
Publication date:
June 8, 2023
Applicant:
Gruenenthal GmbH
Inventors:
Sven KUEHNERT, Rene Michael KOENIGS, Florian JAKOB, Achim KLESS, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER, Klaus SCHIENE, Anita WEGERT
Abstract: A hitherto unknown crystalline form of (?)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.
Type:
Application
Filed:
January 30, 2023
Publication date:
June 8, 2023
Applicant:
Gruenenthal GmbH
Inventors:
Andreas FISCHER, Helmut BUSCHMANN, Michael GRUSS, Dagmar LISCHKE
Abstract: The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.
Type:
Application
Filed:
January 30, 2023
Publication date:
June 8, 2023
Applicant:
Gruenenthal GmbH
Inventors:
Sven KUEHNERT, Rene Michael KOENIGS, Achim KLESS, Anita WEGERT, Paul RATCLIFFE, Ruth JOSTOCK, Thomas KOCH, Klaus LINZ, Wolfgang SCHROEDER, Klaus SCHIENE, Ingo KONETZKI
Abstract: The invention relates to repeated treatment of a neuropathic condition, preferably peripheral neuropathic pain, by application of one or more high-concentration capsaicin and/or capsaicinoid topical dose units, preferably high-concentration capsaicin and/or capsaicinoid patches, to patients who previously did not respond or insufficiently responded to a previous application of one or more high-concentration capsaicin and/or capsaicinoid topical dose units, preferably high-concentration capsaicin and/or capsaicinoid patches or any other high-concentration capsaicin and/or capsaicinoid formulation previously topically administered.
Abstract: Disclosed are non-aqueous solid and liquid compositions comprising resiniferatoxin and a surfactant. The non-aqueous solid and liquid compositions may be used to prepare aqueous compositions that are used in the treatment of pain, specifically osteoarthritis-related joint pain. Moreover, also disclosed are kits containing the non-aqueous solid and liquid compositions and a diluent and methods of preparing the compositions. The non-aqueous solid and liquid compositions allow for longer storage and recovery of resiniferatoxin compared to resiniferatoxin alone prior to reconstitution with a diluent.
Type:
Application
Filed:
October 17, 2022
Publication date:
February 16, 2023
Applicant:
GRUENENTHAL GMBH
Inventors:
Andreas BERNKOP-SCHNUERCH, Olivier VALDENAIRE, Thomas GILLER
Abstract: The present invention relates to compounds according to general formula (I) which act as inhibitors of NaV1.8 and can be used in the treatment of pain.
Type:
Application
Filed:
June 15, 2022
Publication date:
January 26, 2023
Applicant:
GRUENENTHAL GMBH
Inventors:
Sebastian KRUEGER, Sebastian PEIL, Clemens DIALER, Marcel MUELBAIER, Markus WAGENER, Ingo KONETZKI, Nikolay SITNIKOV, Jo ALEN, Martin PETTERSSON
Abstract: An aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration. The composition has excellent storage stability without relying on the presence of high amounts of preservatives.
Type:
Grant
Filed:
October 24, 2019
Date of Patent:
January 10, 2023
Assignee:
Gruenenthal GmbH
Inventors:
Ulrich Reinhold, Marc Schiller, Eva Wulsten, Sabine Karine Katrien Inghelbrecht, Roger Carolus Augusta Embrechts, Ulrich Feil
Abstract: A scored tablet comprises Tapentadol or a physiologically acceptable salt thereof embedded in a prolonged release matrix material; wherein the scored tablet provides prolonged release of Tapentadol or the physiologically acceptable salt thereof; wherein the scored tablet has a site of mechanical weakness along which it can be manually broken into two separate halves preferably having essentially the same size, shape and weight; and wherein the in vitro release profile of the scored tablet essentially corresponds to the in vitro release profile of each of the two separate halves. Also disclosed is a process for the preparation of such a scored tablet.
Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
Type:
Application
Filed:
July 18, 2022
Publication date:
December 15, 2022
Applicant:
GRUENENTHAL GMBH
Inventors:
Jo ALEN, Florian JAKOB, Sebastian KRUEGER, Daniela FRIEBE, Stephanie HENNEN
Abstract: The present invention relates to compounds according to general formula (I) which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
Type:
Application
Filed:
July 18, 2022
Publication date:
November 24, 2022
Applicant:
GRUENENTHAL GMBH
Inventors:
Jo ALEN, Florian JAKOB, Sebastian KRUEGER, Philipp BARBIE, Daniela FRIEBE, Stephanie HENNEN
Abstract: The use of tapentadol for the manufacture of a medicament comprising at least one administration unit A containing dose a of tapentadol and at least one administration unit B containing dose b of tapentadol, where dose a<dose b, for the treatment of pain.
Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
Type:
Application
Filed:
January 5, 2022
Publication date:
April 28, 2022
Applicant:
GRUENENTHAL GMBH
Inventors:
Florian JAKOB, Jo Alen, Sebastian Krueger, Markus Schade, Daniela Friebe, Stephanie Hennen
Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
Type:
Application
Filed:
December 17, 2021
Publication date:
April 7, 2022
Applicant:
GRUENENTHAL GMBH
Inventors:
Florian JAKOB, Jo ALEN, Sebastian KRUEGER, Daniela FRIEBE, Stephanie HENNEN
Abstract: The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glucocorticoid receptor.
Type:
Application
Filed:
December 17, 2021
Publication date:
April 7, 2022
Applicant:
GRUENENTHAL GMBH
Inventors:
Florian JAKOB, Jo ALEN, Sebastian KRUEGER, Philipp BARBIE, Daniela FRIEBE